Skip to main content
Delfa

← All assets

Galantamine

43 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

43

Ongoing

1

Recruiting

1

Completed

35

Sites

305

Countries

23

Endpoints

191

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 191 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
3
Phase 2/3
1
Phase 3
21
Phase 4
10
Not applicable
7

Trials by status

Recruiting
1
Completed
35
Terminated
4
Unknown
3

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
55
Other (unclassified)
33
Caregiver / quality of life
21
Function / daily living
19
Behavior / neuropsychiatric
18
Safety / tolerability / PK
15
Executive function / language
10
Other clinical outcomes
9
Neuroimaging
6
Memory
3
Disease progression
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 57 of 191 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

28

Mini-Mental State Examination (MMSE)Cognition

15

Neuropsychiatric Inventory (NPI)Behavior

9

ADCS-Activities of Daily Living (ADCS-ADL)Function

4

Neuropsychiatric Inventory (NPI)Function

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

43 of 43

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
MAyflOwer RoADA Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

Donepezil, Galantamine, Memantine, Rivastigmine, RO4602522

Alzheimer’s disease

Alzheimer's diseasePh 2Completed142Jun 20151
NCT00679627A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated95Apr 20123results
NCT00000172Evaluation of Galantamine in the Treatment of Alzheimer's Disease

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed55-1
NCT01478633Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed11Jun 2013-
NCT00230997Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

Galantamine

Lewy body dementia

Dementia with Lewy bodiesPh 3Completed5Aug 200417
COMET-ADComparative Research of Alzheimer's Disease Drugs

Donepezil, Galantamine, Rivastigmine

Alzheimer’s disease

Alzheimer's diseaseNot applicableTerminated5Oct 20157results
NCT00299676An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period

Galantamine

Alzheimer’s disease

-Not applicableCompleted5Mar 2008-
NCT00750529Alzheimer and Sleep

Galantamine

Alzheimer’s disease

Age ≥65Ph 1Completed2Sep 2013-
COGICRehabCognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment

Galantamine

Vascular cognitive impairment / dementia

Age 35-75Ph 2Completed1Jun 2016-
NCT07284290Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

Galantamine

Lewy body dementia

Parkinson's disease dementiaPh 4Recruiting1Nov 2029-
NCT01029132Characteristics of Treatment Responders to Galantamine

Galantamine

Alzheimer’s disease

Alzheimer's diseaseNot applicableCompleted1Oct 2009-
NCT00369603Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

Donepezil, Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 4Terminated1Oct 2007-
NCT00814801An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed1Sep 20081results
NCT01181921The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 4Terminated1Jun 2011-results
CASL-AD-01Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Galantamine

Alzheimer’s disease

Alzheimer's diseaseNot applicableUnknown1Dec 2010-
NCT00523666Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 4Unknown1Sep 20084
STREAM-VCISymptomatic Treatment of Vascular Cognitive Impairment

Galantamine, Methylphenidate

Vascular cognitive impairment / dementia

MMSE ≥16Ph 2/3Unknown1Dec 20162
NCT00240695A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

Galantamine

MCI / preclinical Alzheimer’s

Age ≥50Ph 3Completed0May 2004-
NCT00309725A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed0Oct 19991
NCT00216515The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 4Completed0Nov 2005-
NCT00236431A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Galantamine

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Age ≥50Ph 3Completed0Dec 20031
NCT00253214Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Galantamine

Alzheimer’s disease

mild-to-moderate ADPh 3Completed0Jul 20022
NCT00216502A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed0Nov 2005-
NCT00304629Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

Galantamine

Alzheimer’s disease

Age ≥45Ph 3Completed0Mar 20022
NCT00253201A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Galantamine

Alzheimer’s disease

Alzheimer's diseasePh 3Completed0Oct 19972

Showing 1-25 of 43 trials